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AbstrAct
Objectives To determine ages at first capillary sampling 
and notification and age at notification after second 
sampling in Scottish newborns referred with elevated 
thyroid-stimulating hormone (TSH).
subjects and methods Referrals between 1980 and 
2014 inclusive were grouped into seven 5-year blocks 
and analysed according to agreed standards.
results Of 2 116 132 newborn infants screened, 919 
were referred with capillary TSH elevation ≥8 mU/L 
of whom 624 had definite (606) or probable (18) 
congenital hypothyroidism. Median age at first sampling 
fell from 7 to 5 days between 1980 and 2014 (standard 
4–7 days), with 22, 8 and 3 infants sampled >7 days 
during 2000–2004, 2005–2009 and 2010–2014. 
Median age at notification was consistently ≤14 days, 
range falling during 2000–2004, 2005–2009 and 
2010–2014 from 6 to 78, 7–52 and 7–32 days with 12 
(14.6%), 6 (5.6%) and 5 (4.3%) infants notified >14 
days. However 18/123 (14.6%) of infants undergoing 
second sampling from 2000 onwards breached the 
≤26-day standard for notification. By 2010–2014, the 
91 infants with confirmed congenital hypothyroidism had 
shown favourable median age at first sample (5 days) 
with start of treatment (10.5 days) approaching age at 
notification.
conclusion Most standards for newborn thyroid 
screening are being met by the Scottish programme, 
but there is a need to reduce age range at notification, 
particularly following second sampling. Strategies 
to improve screening performance include carrying 
out initial capillary sampling as close to 96 hours as 
possible; introducing 6-day laboratory reporting and 
use of electronic transmission for communicating repeat 
requests. 
IntrOductIOn
The effective running of a Newborn Screening 
service depends on timely sampling of the infant: 
an adequate transport system between the home 
or hospital and the laboratory; prompt laboratory 
testing; and efficient communication of the results 
to the clinician so as to permit early review and, 
where appropriate, treatment. Once alerted, the 
clinician must ensure that the infant is seen for clin-
ical and further laboratory assessment within days if 
not hours of notification.
In Scotland, capillary blood spot screening for 
thyroid-stimulating hormone (TSH) measurement 
has been used in the detection of primary congen-
ital hypothyroidism since August 1979. The first 
survey of this screening programme showed that in 
the early years, late screening of infants was rela-
tively common,1 attributable in part to the miscon-
ception that heel prick testing should be delayed 
until the child was on milk so as to avoid a false 
negative result with concurrent phenylketonuria 
screening. A second survey of the Scottish newborn 
screening programme showed improvement, but 
that late sampling remained a problem, particularly 
in inpatients.2
A further problem concerns the interval between 
the first and second sample when repeat sampling 
is necessary following a borderline test. The 2006 
evaluation showed a reasonable median interval (11 
days) but a wide range (up to 52 days).2
What this study adds?
 ► Initial sampling was carried out within the 
required standard of ≤7 days in 115/118 (97%) 
of referrals in Scotland between 2010 and 2014.
 ► Median notification age after initial sampling 
was 11 (9 11) days from 1990. Nevertheless, 
23/282 (8%) infants breached the ≤14 day 
standard between 2010–2014.
 ► Notification age following second sampling 
remains relatively unsatisfactory with 14.6% 
patients breaching the 26-day standard 2000-
2014. Improvement strategies include sampling 
at 96 hours and 6-day reporting.
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What is already known?
 ► Effective newborn screening for hypothyroidism 
requires timely capillary sampling for thyroid-
stimulating hormone (TSH) measurement, 
efficient sample processing and prompt 
notification of an abnormal result.
 ► Previous work in Scotland has shown that 
when a repeat sample is requested the interval 
between first and second samples may exceed 
3 weeks.
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table 1 Age at initial capillary sampling in Scottish infants referred with TSH elevation during seven 5-year time periods from 1980 to 2014 
(required standard =≤7 days)
time period referred, n
Median, 
days tested at 4–7 days, n (%) tested 8–10 days, n,(%) tested >10 days, n (%) unknown
1980–1984 95 7 56 (58.9) 27 (28.4) 11 (11.5) 1
1985–1989 147 6 105 (71.4) 27 (18.3) 15 (10.2) 0
1990–1994 119 7 83 (69.7) 24 (20.1) 10 (8.4) 2
1995–1999 112 6 93 (83.0) 14 (12.5) 4 (3.5) 1
2000–2004 150 6 123 (82.0) 17 (11.3) 10 (6.6) 1
2005–2009 156 5 144 (92.3) 7 (4.4) 3 (1.9) 2
2010–2014 140 5 136 (96.4) 3 (2.1) 2 (1.4) 0
n, number; TSH, thyroid-stimulating hormone.
The purpose of the present study is to re-evaluate the screening 
programme by dividing the period 1980 to 2014 into seven 
5-year blocks and measuring performance against key standards 
including age at first blood spot testing and notification and time 
taken for notification after second sampling.
PAtIents And MethOds
The Scottish Congenital Hypothyroid database was 
cross checked with the Newborn Screening Laboratory and the 
information grouped into seven 5-year periods: 1980–1984, 
1985–1989, 1990–1994, 1995–1999, 2000–2004, 2005–2009 
and 2010–2014.
The data were analysed according to diagnostic category 
and agreed standards. Patients were assigned to four diagnostic 
groups: definite congenital hypothyroidism, probable congenital 
hypothyroidism, transient TSH elevation and status uncertain as 
described previously by Jones et al.2
The following standards were agreed:
1. Age at initial capillary sampling was set at 4–7 days. This is in 
keeping with the pregnancy and newborn quality indicators 
published in 2013 by Health Improvement Scotland which 
state that the optimum time period for blood spot sampling 
is between 96 and 120 hours of age and no later than 
168 hours.3
2. Interval between sampling and laboratory receipt was set at 
4 days. The majority of samples are sent in prepaid first class 
envelopes by Royal Mail to the laboratory, with a few areas 
within Scotland choosing to use a courier. This standard 
takes account of the delay introduced by weekends during 
which there is no Saturday or Sunday postal delivery and no 
laboratory service.
3. Notification of a positive blood spot result requiring imme-
diate referral to a clinician was set at 14 days using the capil-
lary TSH cut-offs from 1979 to the present which have been 
described previously,4 with ≥25 mU/L whole blood from 
2002 onwards. This standard allows 7 days for sampling, 
4 days for sample transfer and 3 days for the laboratory 
to process the blood spot sample, initiate further testing 
when required and then communicate a positive result by 
telephone.
4. A 26-day standard was set for notification of a positive result 
following a second sample, with TSH cut-off ≥ 8 mU/L 
since 2002.4 This standard allows 14 days to establish that a 
repeat sample is required as described above, 2 days to notify 
the Community Child Health unit responsible that a repeat 
is necessary, given that some health boards do not accept 
communication by electronic mail, 1 day for child health to 
notify the midwife, 2 days for the midwife to take the sample, 
4 days for transit to the laboratory and 3 days for processing.
5. No standard was set for age at starting L-T4 treatment since 
this decision depends on clinical assessment as well as the 
degree of capillary TSH elevation at the time of referral.4 
However, for most infants it was expected that treatment 
would be on or after the day of notification, in keeping with 
paediatric practice in the UK.5
ethical aspects
Since 2005, informed consent has been sought for entry onto 
the Congenital Hypothyroid database with retrospective consent 
being obtained where possible thereafter. The project was regis-
tered with the Clinical Effectiveness Department of National 
Health Service Greater Glasgow and Clyde as a quality improve-
ment project.
Analysis of data
Each standard was assessed according to the seven time periods 
and with particular emphasis on performance of the screening 
programme since 2000. Data are expressed as median, mean ± 
SEM, lower quartile (Q1) and upper quartile (Q3) either in table 
form or as box and whisker plots. Mann-Whitney testing was 
used to detect significant differences between 5-year blocks.
results
Between January 1980 and December 2014, the laboratory 
screened 2 116 132 newborns, of whom 919 infants were 
referred with capillary TSH elevation: 606 (65.9%) with 
definite congenital hypothyroidism, 18 (1.9%) with probable 
congenital hypothyroidism, 51 (5.5%) with status uncertain, 
211 (22.9%) with transient TSH elevation and 33 with insuf-
ficient data.
Initial capillary sampling
Table 1 shows a significant fall in the number of infants 
sampled >7 days after 1994 (p≤0.01) with a plateau between 
1995–1999 and 2000–2004 but a progressive decrease there-
after (p<0.001). Between 2000–2004, 2005–2009 and 2010–
2014, 27, 10 and 5 infants were sampled late. Three of the five 
most recent infants were hospitalised at the time of sampling, 
including one with meningomyelocele and one with aortic 
coarctation.
evaluation of interval between initial sampling and 
laboratory receipt
Median interval between initial testing and receipt by the labo-
ratory was within the required 4 days throughout the study 
(figure 1). Between 2000 and 2004 19/150 (12.6%) infants 
breached the standard, with 15/156 (9.6%) breaching between 
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Figure 1 Box and whisker plot showing interval (days) between initial sampling and laboratory receipt in infants referred with capillary thyroid-
simulating hormone elevation in Scotland between 1980 and 2014, grouped in seven 5-year time periods. Outliers are represented by asterisks.
Figure 2 Box and whisker plot showing age at notification after single sampling in Scottish infants referred with capillary thyroid stimulating 
hormone elevation between 1980 and 2014, grouped into seven 5-year time periods. The dotted horizontal line represents the standard of 14 days for 
notification.
2005 and 2009 and 20/141 (14.1%) between 2010 and 2014. 
During these time periods, the number of infants with an 
interval exceeding 5 days fell from 25 to 21 and 6. All of 
the latter six infants were well, term babies who had been 
discharged from five different maternity units across Scotland.
Age at notification following single sampling
Median and mean ages at notification fell within the 14-day stan-
dard from 1980 to 2014 (see figure 2). Following a significant 
reduction from 13 and 12 days during 1980–1989 to 11 days 
in 1990-1994 (p=<0.001), age at notification remained ≤11 
days thereafter. During the three 5-year periods from 2000 to 
2014 age range at notification narrowed, falling from 6 to 78 
to 7–52 and then 7–32 days; with 12 (14.6%), 6 (7.2%) and 4 
(5.3%) infants notified >14 days during these periods. Reason 
for late notification in the 4 cases from 2010 to 14 was late 
sampling at 9 and 15 days in two and late receipt (day 15) in one. 
The fourth patient had a pre-emptive venous blood sample taken 
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table 2 Age at notification (days) in 198 infants requiring second sampling (standard ≤26 days) 
time period total referred retested (n (%))
Age at notification
notified
≤26 days (n (%))
notified
>26 days (n (%)) not known
Median
(range)
Mean±sd
(Q1–3)
1980–1984 95 9 (9.4) 14.5 (11–41) 19.3±10.2 (12.5–24.5) 7 (77.7) 1 (11.2) 1
1985–1989 147 28 (19) 20.5 (7–33) 19.1±7.8 (11–24.5) 23 (82.1) 5 (17.8) 0
1990–1994 119 14 (11.7) 22 (8–31) 20.4±6.7 (18−24) 12 (85.7) 2 (14.2) 0
1995–1999 112 24 (21.4) 19 (8–35) 19±7.2 (13−22) 20 (83.4) 3 (12.5) 1
2000–2004 150 37 (24.7) 21 (7–50) 21.4±9.3 (15.5–25) 28 (75.6) 8 (21.6) 1
2005–2009 156 41 (26.2) 20 (5–56) 21±9.1 (16–24) 35 (85.3) 6 (14.6) 0
2010–2014 140 45 (31.9) 19 (9–39) 19.6±5.6 (16–21) 41 (91.2) 4 (8.8) 0
This table does not show data on 31 infants tested three times during the study period.
Q1, lower quartile; Q3, upper quartile. 
table 3 Age (days) at initial testing, notification and start of treatment in 623 of 624 infants with true congenital hypothyroidism referred by 
Scottish Screening laboratory 1980–2014
time period
Age at initial sampling Age at notification Age at start of treatment
Median
(range)
Mean±seM
(Q1-3)
Median
(range)
Mean±seM
(Q1-3)
Median
(range)
Mean±seM
(Q1-3)
1980–1984 n=79 7 (4–56) 7.8+/−5.9 (6–8) 13 (5–59) 14.4+/−6.5 (11–17) 16 (8–313) 21+/−35.3 (13–19)
1985–1989 n=91 6 (4–35) 6.7+/−3.4 (5–7) 12 (8–43) 12.9+/−5.6 (10–14) 13 (8–212) 17.4+/−23 (11–16)
1990–1994 n=85 6 (4–49) 7.2+/−5 (5–7.5) 11 (5–54) 13.3+/−9 (10–13) 12 (2–195) 16.5+/−22.7 (10–15)
1995–1999 n=85 6 (1–13) 5.9+/−1.6 (5–7) 10 (5–38) 11.2+/−5.6 (8–12) 11 (1–177) 16.8+/−27 (8–13)
2000–2004 n=90 6 (3–17) 6.1+/−1.6 (5–7) 11 (3–31) 12+/−4.2 (10–13) 12 (3–200) 17.4+/-27.4 (10–14)
2005–2009 n=102 5 (1–12) 5.2+/−1.2 (5–6) 11 (5–56) 12.5+/−7.1 (9–13) 11.5 (1–94) 13.4+/−10 (10–14)
2010–2014 n=91 5 (4–15) 5+/−1.2 (4–5) 10 (7–31) 11.7+/−4.6 (9–12) 10.5 (1–48) 11.9+/−6 (9–13)
Q1, lower quartile; Q3, upper quartile.
by the neonatal team rather than the second sample requested by 
the screening laboratory.
Age at notification following second sampling
Table 2 shows the increase in retesting during the study period 
which reached 31.9% by 2010–2014. Of the 229 infants requiring 
retesting—twice in 198 and three times in 31—the median 
(range) birth weight and gestation was 3000 g (660–5060 g) 
and 39 (25–42) weeks, with 53 (23.1%) weighing <2500 g, 46 
(20%) born before 37 weeks gestation and 64 (27.9%) known 
to be sick at the time of initial sampling. Congenital hypothy-
roidism was confirmed in 74 (32.3%) of these infants, with tran-
sient TSH elevation in 83 (36.2%) and status still uncertain in 
72 (31%).
During 2000–2004, 2005–2009 and 2010–2014, the numbers 
of infants sampled twice who breached the 26-day standard were 
8/37 (21.6%), 6/41 (14.6%) and 4/45 (8.8%), 4 with confirmed 
congenital hypothyroidism, 10 with transient TSH elevation and 
4 with status uncertain.
screening trends in infants with definite and probable 
congenital hypothyroidism
Table 3 shows an improvement in median age and a narrowing 
of age range at initial sampling between 1980–1984 and 
2010–2014. Median age at start of treatment improved signifi-
cantly from 16 and 13 days between 1980 and 1989 down to 
11–12 days during 1990–2004 (p<0.001) with a smaller and 
non-significant fall to 11.5 and 10.5 days during 2005–2009 
and 2010–2014 as it approached the day of notification. From 
2002, the year that the current autoDelfia TSH assay came into 
use, 21 infants started treatment >26 days of whom 10 had 
definite congenital hypothyroidism, 8 transient TSH elevation 
and 3 status uncertain. Testing had been carried out twice in 
14, three times in 4 and once in only 3. Median (range) birth 
weight was 3.07 (0.69–4.18 kg) (7 infants<2500g) and gestation 
39 (26–42) weeks (seven infants<37 weeks) and 8 infants were 
logged as ‘sick’. Thirteen infants started treatment aged 27–40 
days, attributable to repeat testing alone (3), surveillance of low 
grade TSH elevation (1) and both repeat testing and surveillance 
(9). Four infants started treatment aged between 41 and 55 days 
owing to delayed initial sampling at 31 days in an extremely sick, 
preterm and low birthweight infant (birth weight 690 g at 29 
weeks gestation) in whom capillary TSH was 127 mU/L; delayed 
repeat sampling at 39 days in an infant with multiple congenital 
malformations; and late notification at 31 and 49 days in two 
preterm infants (31 and 27 weeks) who had been tested three 
times. Four infants started treatment very late at 81, 94, 127 
and 200 days, reflecting prolonged surveillance of modest TSH 
elevation.
dIscussIOn
The goal of newborn screening for congenital hypothyroidism is 
to ensure that affected infants start treatment as soon as possible, 
so that neurological impairment is either prevented or minimised. 
The European Society for Paediatric Endocrinology (ESPE) 
consensus paper of Léger et al states that thyroxine treatment 
should be started as soon as possible and not later than within 
the first 2 weeks of life.6 This recommendation was graded as 
a ‘strong’ but with only ‘moderate’ evidence, using the scheme 
of Swiglo et al7 since the value of starting treatment at 14 days 
rather than a week later remains unproven. However, starting 
thyroxine beyond 21 days has been shown to affect outcome,8 
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while infants with athyreosis will display unwanted symptoms 
such as jaundice and feeding difficulties within the first week of 
life and hence benefit from early treatment.9
A prerequisite of starting thyroxine treatment promptly is 
timely heel prick sampling. The present study shows that virtu-
ally all infants in Scotland are now tested within the Scottish 
standard of 4–7 days, with median age at first sampling falling to 
5 days, compared with the 6 days reported in the latter half of 
the 2006 audit by Jones et al.2 There has also been a steady drop 
in the numbers of infants breaching the 7-day standard, with 
only five during 2010–2014. It is noteworthy that three of these 
infants were sick and/or had prolonged hospital stay, indicating 
the need for continuing vigilance in hospitalised infants.
The standard chosen for age at initial sampling in Scotland 
contrasts with the ESPE guidelines which state that the best 
window of opportunity for testing babies is 48–72 hours of age.6 
In fact, the most recent Scottish guidelines specify that sampling 
should take place ‘as soon as possible after 96 hours’ (4 days),10 
while the English Newborn Blood Spot Screening Programme 
guidelines from September 2015 state that screening should 
be on day 5 of life.11 The rationale of testing after 48 hours of 
life is to avoid the effect of the postnatal TSH surge described 
by Fisher et al.12 Bringing forward the mean day of sampling 
from day 5 to day 3 in Scotland would improve the performance 
of the thyroid screening programme as well as conferring the 
added benefit of early detection of inborn errors of metabolism 
such as medium-chain acyl-CoA dehydrogenase deficiency13 
and maple syrup urine disease. However, this would have major 
logistic implications, particularly concerning immunoreac-
tive trypsinogen sampling for cystic fibrosis which is currently 
recommended at 5 days in the UK14 although carried out earlier 
elsewhere, for example, at 24–36 hours in Michigan.15
As shown in figure 1, the interval between sampling and labo-
ratory receipt processing of samples was consistently within 
the standard of 4 days throughout the study period while age 
at notification following single sampling also showed a favour-
able trend (see figure 2). Test results for notification were seen 
during 2010–2014 when median age was down to 10 days and 
range reduced to 7–32 days with only four infants notified 
after the 14-day standard. By contrast, the timelines for repeat 
sampling are less satisfactory. Thus, 18/123 (14.6%) of infants 
undergoing second sampling during the past 15 years have 
breached the ≤26 day standard for notification. This stan-
dard is in fact more generous than the 2013 UK Initial Clin-
ical Referral Standards and Guidelines which sets 14 and 21 
days as achievable standards for starting treatment with L-T4 
following initial and repeat sampling by 14 days after a single 
sample and 21 days after a repeat blood sample.16
Concerning age at starting treatment it should be noted that 
while median/upper quartile fell from 16/19 during 1990–
1994 to 10.5/13 during 2010–2014, some patients started 
thyroxine well after the neonatal period throughout the study 
(see table 3). Analysis of the 21 patients starting treatment late 
(>26 days) from 2002 onwards shows the key factors to be: 
a predominance of preterm and low birthweight infants with 
modest initial capillary TSH prompting repeat testing (partic-
ularly when three tests are requested); late retesting (and in 
the case of one infant very late initial testing) in the context 
of extreme prematurity and neonatal sickness; and modest 
TSH elevation on retesting, resulting in surveillance rather 
than prompt treatment. In Scotland, a borderline result (8–25 
mU/L) is notified by the screening laboratory to the Community 
Child Health (CCH) unit within each Scottish Health Board. 
While most CCH units accept electronic mail, some will only 
accept Royal Mail requests. The CCH unit then has to identify 
the appropriate midwifery team. Each unit has its own system 
for notifying the midwifery service, most units preferring noti-
fication by facsimile. There is no nationally agreed deadline set 
for the midwives to collect the repeat sample.
Based on the findings of this study, we recommend the 
following changes to improve the screening programme in 
Scotland, particularly concerning the problem posed by repeat 
sampling:
1. Bringing the age at initial capillary sampling as close to 
96 hours of life as possible, consistent with the Scottish 
guidelines.12
2. Introducing 6-day laboratory reporting so that results are 
transmitted on Saturdays, as well as weekdays, this proposal 
is currently awaiting approval from the commissioners of 
newborn screening in Scotland.
3. Insisting on electronic transmission of repeat requests from 
Screening Laboratory to CCH and from CCH to community 
midwife.
A further measure to improve the efficiency of repeat testing 
would be to fund a liaison nurse practitioner, based in the 
screening laboratory. This measure would accelerate the time 
taken to communicate the need for repeat sampling, oversee 
timely repeat sampling in the community and prompt laboratory 
receipt/processing and rapid communication of the result to the 
clinician.
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